On June 14, 2021 Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, reported it will host an analyst and investor event on Monday, June 21 at 4:30 pm ET (Press release, Sierra Oncology, JUN 14, 2021, View Source [SID1234583947]). The event will feature three leading myelofibrosis experts:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Aaron Gerds, MD, Taussig Cancer Institute, Cleveland Clinic
Stephen Oh, MD, PhD, Siteman Cancer Center, Washington University School of Medicine
Srdan Verstovsek, MD, PhD, University of Texas; MD Anderson Cancer Center
The call will include an overview of momelotinib data presented at the European Hematology Association (EHA) (Free EHA Whitepaper) Annual Meeting, a panel discussion moderated by Barbara Klencke, MD, Chief Medical Officer of Sierra Oncology, and an open question & answer session with attendees.
Analyst & Investor Event and Webcast Information
Date and Time: Monday, June 21, 2021 at 4:30 pm ET
To register, please click here.
The presentation will be webcast live, and an archive of the presentation will be accessible after the event through the Sierra Oncology website: www.SierraOncology.com.
About Momelotinib
Momelotinib is a selective and orally bioavailable JAK1, JAK2 and ACVR1 / ALK2 inhibitor for the potential treatment of myelofibrosis. Myelofibrosis results from dysregulated JAK-STAT signaling and is characterized by constitutional symptoms, splenomegaly (enlarged spleen) and progressive anemia.
Momelotinib is currently under investigation in the MOMENTUM clinical trial, a global, randomized, double-blind Phase 3 study for symptomatic and anemic myelofibrosis patients. Top-line data are anticipated in Q1 2022. The U.S. Food & Drug Administration has granted Fast Track designation for momelotinib.